ECSP19026973A - Derivados de naftiridinona y su uso en el tratamiento de la arritmia - Google Patents

Derivados de naftiridinona y su uso en el tratamiento de la arritmia

Info

Publication number
ECSP19026973A
ECSP19026973A ECSENADI201926973A ECDI201926973A ECSP19026973A EC SP19026973 A ECSP19026973 A EC SP19026973A EC SENADI201926973 A ECSENADI201926973 A EC SENADI201926973A EC DI201926973 A ECDI201926973 A EC DI201926973A EC SP19026973 A ECSP19026973 A EC SP19026973A
Authority
EC
Ecuador
Prior art keywords
arrhythmia
treatment
present
naphthyridinone derivatives
naphthyridinone
Prior art date
Application number
ECSENADI201926973A
Other languages
English (en)
Inventor
Kayo Yasoshima
Ken Yamada
Stefan Peukert
Yunshan Peng
Ruowei Mo
Fupeng Ma
Efthymiou Hatice Belgin Gulgeze
Sicong Geng
Guillaume Barbe
David Thomas Parker
Lv Liao
Gregory Raymond Bebernitz
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP19026973A publication Critical patent/ECSP19026973A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona un compuesto de fórmula (I) o una sal farmacéuticamente aceptable del mismo; (I) donde R1, R3–R6, X2 y X3 son como se define en la presente descripción, un método para elaborar los compuestos de la invención, y sus usos terapéuticos. La presente invención además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica.
ECSENADI201926973A 2016-10-21 2019-04-15 Derivados de naftiridinona y su uso en el tratamiento de la arritmia ECSP19026973A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662410930P 2016-10-21 2016-10-21
CN2016102928 2016-10-21
US201662413292P 2016-10-26 2016-10-26

Publications (1)

Publication Number Publication Date
ECSP19026973A true ECSP19026973A (es) 2019-04-30

Family

ID=60409317

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI201926973A ECSP19026973A (es) 2016-10-21 2019-04-15 Derivados de naftiridinona y su uso en el tratamiento de la arritmia

Country Status (31)

Country Link
US (3) US10266531B2 (es)
EP (2) EP3529251B1 (es)
JP (1) JP7030802B2 (es)
KR (1) KR102540872B1 (es)
CN (1) CN109843887B (es)
AU (2) AU2017344489C1 (es)
CL (1) CL2019001023A1 (es)
CO (1) CO2019003894A2 (es)
CR (1) CR20190201A (es)
CU (1) CU24599B1 (es)
DO (1) DOP2019000100A (es)
EC (1) ECSP19026973A (es)
ES (1) ES2934234T3 (es)
FI (1) FI3529251T3 (es)
HR (1) HRP20221516T1 (es)
HU (1) HUE060882T2 (es)
IL (1) IL266128B (es)
JO (1) JOP20190086A1 (es)
LT (1) LT3529251T (es)
MX (1) MX390044B (es)
PE (1) PE20190735A1 (es)
PH (1) PH12019500849A1 (es)
PL (1) PL3529251T3 (es)
PT (1) PT3529251T (es)
RS (1) RS63841B1 (es)
SA (1) SA519401614B1 (es)
SG (1) SG11201902529WA (es)
SI (1) SI3529251T1 (es)
TW (1) TWI759343B (es)
UY (1) UY37445A (es)
WO (1) WO2018073788A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
ES2950007T3 (es) * 2018-06-27 2023-10-04 Bristol Myers Squibb Co Compuestos de naftiridinona útiles como activadores de células T
WO2022074567A1 (en) * 2020-10-06 2022-04-14 Novartis Ag Pharmaceutical compositions comprising naphthyridinone derivatives and their use in the treatment of arrhythmia
CN115677739B (zh) * 2021-07-31 2025-09-30 华南理工大学 一种o,o-二氟化硼配合物的制备方法
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno
WO2024061371A1 (zh) * 2022-09-23 2024-03-28 广州威诺森医药科技有限公司 一种骈环吡啶类甾体合成酶抑制剂及其制备方法和应用
KR20260015867A (ko) * 2023-05-24 2026-02-03 노파르티스 아게 질환 또는 장애 치료용 나프티리디논 유도체

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1022214A (en) 1963-01-31 1966-03-09 Sterling Drug Inc Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation
IL51092A0 (en) 1976-12-10 1977-02-28 Abic Ltd Naphthyridine derivatives and their preparation
JPS57176959A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd 1-(2',6'-dichlorophenyl)-2,3bis(methylthio) indole and its preparation
JPS57176957A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone
JPS57176958A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd 1-(2',6'-dichlorophenyl)-2-methylthioindole and its preparation
JPS57176956A (en) 1981-04-24 1982-10-30 Nissan Chem Ind Ltd Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4559332A (en) 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US4698341A (en) 1983-07-30 1987-10-06 Godecke Aktiengesellschaft Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis
US4767762A (en) * 1985-12-23 1988-08-30 Abbott Laboratories Tricyclic quinoline and naphthyride antibacterials
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
DE69129226T2 (de) 1990-01-24 1998-07-30 Douglas I. Woodside Calif. Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
IL101860A0 (en) 1991-05-31 1992-12-30 Ici Plc Heterocyclic derivatives
EP0618803A4 (en) 1991-12-19 1995-03-22 Southwest Found Biomed Res POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS.
IL111785A0 (en) 1993-12-03 1995-01-24 Ferring Bv Dp-iv inhibitors and pharmaceutical compositions containing them
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE69531305T2 (de) 1994-10-20 2004-05-13 Wakunaga Seiyaku K.K. Pyridoncarboxylat- derivate oder salze davon und antibakterielle zusammensetzungen die diese als aktiven bestandteil enthalten
JP3484703B2 (ja) 1996-04-19 2004-01-06 湧永製薬株式会社 新規ピリドンカルボン酸誘導体又はその塩並びに該物質を有効成分とする抵抗剤
DE122010000020I1 (de) 1996-04-25 2010-07-08 Prosidion Ltd Verfahren zur Senkung des Blutglukosespiegels in Säugern
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
DE69724140T2 (de) 1996-11-28 2004-06-03 Wakunaga Pharmaceutical Co., Ltd. Pyridoncarbonsäurederivate oder ihre salze und diese als aktive bestandteile enthaltende medikamente
JP2002517486A (ja) 1998-06-12 2002-06-18 バーテックス ファーマシューティカルズ インコーポレイテッド ｐ３８のインヒビター
EP1107759A1 (en) 1998-08-03 2001-06-20 Basf Corporation Pyridinones for the treatment of sexual dysfunction
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
US6544974B2 (en) 1999-09-23 2003-04-08 G.D. Searle & Co. (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesteryl ester transfer protein activity
AU7393801A (en) 2000-04-12 2001-10-23 Novartis Ag Combination of organic compounds
JP2003040866A (ja) 2001-07-31 2003-02-13 Nippon Kayaku Co Ltd Ｎ置換インドール誘導体、その製造法及びそれを有効成分とする害虫防除剤
KR20040041177A (ko) * 2001-09-26 2004-05-14 바이엘 파마슈티칼스 코포레이션 당뇨병 치료제로서의 1,6-나프티리딘 유도체
WO2003063781A2 (en) 2002-01-29 2003-08-07 Merck & Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
ES2274268T3 (es) 2002-05-31 2007-05-16 Bayer Pharmaceuticals Corporation Compuestos y composiciones para el tratamiento de la diabetes y trastornos relacionados con la diabetes.
DK1537114T3 (da) 2002-08-07 2006-11-13 Novartis Ag Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande
PT1565463E (pt) 2002-11-18 2008-09-10 Novartis Ag Derivados de imidazo[1,5-a]piridina e métodos para tratar doenças mediadas pela aldosterona
US20060194782A1 (en) 2003-09-18 2006-08-31 Altana Pharma Ag Pharmacologically active imidazo[4,5-c] pyridines
EP1667685B1 (en) 2003-09-23 2012-03-14 Merck Sharp & Dohme Corp. Quinazoline potassium channel inhibitors
ATE433984T1 (de) 2004-03-26 2009-07-15 Lilly Co Eli Verbindungen und verfahren zur behandlung von dyslipidämie
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
DE102004018198A1 (de) 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
TW200611898A (en) 2004-05-28 2006-04-16 Speedel Experimenta Ag Organic compounds
CN1960991A (zh) 2004-05-28 2007-05-09 斯皮德尔实验股份公司 用作醛固酮合酶抑制剂的四氢咪唑并[1,5－a]吡啶衍生物
ATE490241T1 (de) 2004-05-28 2010-12-15 Novartis Ag Heterocyclische verbindungen und deren verwendung als aldosteronsynthaseinhibitoren
MX341797B (es) 2004-06-24 2016-09-02 Vertex Pharmaceuticals Incorporated * Moduladores de transportadores con casete de union con atp.
TW200611897A (en) 2004-07-09 2006-04-16 Speedel Experimenta Ag Organic compounds
DE102004054215A1 (de) 2004-11-10 2006-05-11 Merck Patent Gmbh Pyridopyrimidinonderivate
TW200716105A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Imidazole compounds
TW200716634A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
JP5237799B2 (ja) 2005-06-27 2013-07-17 エグゼリクシス パテント カンパニー エルエルシー ピラゾールベースのｌｘｒモジュレーター
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
EP1783114A1 (en) 2005-11-03 2007-05-09 Novartis AG N-(hetero)aryl indole derivatives as pesticides
US8883841B2 (en) 2005-11-23 2014-11-11 The Board Of Regents Of The University Of Texas System Oncogenic ras-specific cytotoxic compound and methods of use thereof
AR056888A1 (es) 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
EP2009080A4 (en) 2006-04-04 2010-05-26 Taiyo Nippon Sanso Corp METHOD OF REMOVING METHANE, METHANE PARATOR AND METHOD USE SYSTEM
TW200808813A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
TW200808812A (en) 2006-04-12 2008-02-16 Speedel Experimenta Ag Imidazo compounds
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
CN101506216A (zh) 2006-08-25 2009-08-12 诺瓦提斯公司 用于治疗由醛固酮合酶和/或11-β-羟化酶和/或芳香酶介导的病症的稠合的咪唑衍生物
CN101605777A (zh) 2006-12-18 2009-12-16 诺瓦提斯公司 作为醛固酮合酶抑制剂的咪唑类化合物
KR20090090395A (ko) 2006-12-18 2009-08-25 노파르티스 아게 4-이미다졸릴-1,2,3,4-테트라히드로퀴놀린 유도체 및 알도스테론/11-베타-히드록실라제 억제제로서의 그의 용도
MX2009006481A (es) 2006-12-18 2009-06-26 Novartis Ag Derivados de imidazol 1-sustituidos, y su uso como inhibidores de la sintasa de aldosterona.
ATE484507T1 (de) 2007-03-29 2010-10-15 Novartis Ag Heterocyclische spiroverbindungen
UA103018C2 (uk) * 2008-02-22 2013-09-10 Оцука Фармасьютікал Ко., Лтд. Сполуки бензодіазепіну і фармацевтична композиція
WO2010012745A2 (en) 2008-07-29 2010-02-04 Boehringer Ingelheim International Gmbh Benzimidazoles
EP2464654B1 (en) 2009-08-10 2014-10-08 UCL Business PLC Thiol protecting group
GB0917571D0 (en) 2009-10-07 2009-11-25 Karobio Ab Novel estrogen receptor ligands
KR101477156B1 (ko) 2010-08-25 2014-12-29 (주)네오팜 신규한 헤테로고리 화합물 및 이를 이용한 염증성 질환 치료용 조성물
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
CA2839395A1 (en) 2011-07-12 2013-01-17 F. Hoffmann-La Roche Ag Aminomethyl quinolone compounds
WO2013112932A1 (en) 2012-01-27 2013-08-01 Gilead Sciences, Inc. Combination therapies using late sodium ion channel blockers and potassium ion channel blockers
CA2873861C (en) 2012-04-05 2021-01-19 Boehringer Ingelheim International Gmbh Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase
US9067894B1 (en) 2013-03-07 2015-06-30 Vanderbilt University Compound, composition, and method of activating GIRK potassium channel and use of same for treating conditions of interest
WO2014152317A2 (en) 2013-03-15 2014-09-25 Melinta Therapeutics, Inc. Methods of treating gonorrhea infections using quinolone antibiotics
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AR096022A1 (es) 2013-04-11 2015-12-02 Basf Se Compuestos de pirimidinio sustituido, útiles para combatir plagas de animales
WO2015019347A1 (en) 2013-08-08 2015-02-12 Yeda Research And Development Company Ltd. Girk as a therapeutic target of immune disorders and a marker of b cell subtypes
JP2015143209A (ja) 2013-12-26 2015-08-06 学校法人近畿大学 ピリドンカルボン酸系抗菌薬のアルコキシカルボニルヘミアセタール型エステルプロドラッグ
AU2015304851A1 (en) 2014-08-21 2017-02-23 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides as RIP1 kinase inhibitors as medicaments
WO2016198342A1 (de) * 2015-06-09 2016-12-15 Bayer Pharma Aktiengesellschaft Positiv allosterische modulatoren des muskarinergen m2 rezeptors
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب

Also Published As

Publication number Publication date
US20190263803A1 (en) 2019-08-29
KR20190066052A (ko) 2019-06-12
US20210284635A1 (en) 2021-09-16
IL266128B (en) 2021-06-30
EP3529251A1 (en) 2019-08-28
PT3529251T (pt) 2022-12-23
AU2017344489A1 (en) 2019-04-11
JP7030802B2 (ja) 2022-03-07
AU2017344489B2 (en) 2020-04-02
CN109843887A (zh) 2019-06-04
US11530213B2 (en) 2022-12-20
JOP20190086A1 (ar) 2019-04-18
RU2019115344A3 (es) 2021-02-20
CN109843887B (zh) 2022-05-10
PL3529251T3 (pl) 2023-01-30
CU20190042A7 (es) 2019-11-04
AU2017344489C1 (en) 2021-12-23
CR20190201A (es) 2019-06-04
TWI759343B (zh) 2022-04-01
WO2018073788A1 (en) 2018-04-26
RU2019115344A (ru) 2020-11-24
US20180111932A1 (en) 2018-04-26
BR112019007863A2 (pt) 2019-07-02
SI3529251T1 (sl) 2023-01-31
FI3529251T3 (fi) 2023-01-13
SG11201902529WA (en) 2019-05-30
AU2020204341A1 (en) 2020-07-16
ES2934234T3 (es) 2023-02-20
CO2019003894A2 (es) 2019-04-30
IL266128A (en) 2019-06-30
CL2019001023A1 (es) 2019-06-21
CA3038624A1 (en) 2018-04-26
HRP20221516T1 (hr) 2023-02-17
EP4141006A1 (en) 2023-03-01
SA519401614B1 (ar) 2022-06-12
DOP2019000100A (es) 2019-06-16
JP2019531326A (ja) 2019-10-31
KR102540872B1 (ko) 2023-06-08
CU24599B1 (es) 2022-06-06
PE20190735A1 (es) 2019-05-23
AU2020204341B2 (en) 2021-07-01
US10844055B2 (en) 2020-11-24
LT3529251T (lt) 2023-01-10
MX2019004484A (es) 2019-08-05
TW201819377A (zh) 2018-06-01
HUE060882T2 (hu) 2023-04-28
US10266531B2 (en) 2019-04-23
RS63841B1 (sr) 2023-01-31
UY37445A (es) 2018-05-31
EP3529251B1 (en) 2022-10-05
PH12019500849A1 (en) 2019-12-02
MX390044B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
GT201600269A (es) Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble
CO2017013708A2 (es) Macrociclos peptídicos contra acinetobacter baumannii.
MX383686B (es) Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn.
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
UY35273A (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn
MX2018011102A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CO2020005885A2 (es) Derivados de piridinona y su uso como inhibidores selectivos de alk-2
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
ECSP19084722A (es) Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MX2021012499A (es) Inhibidores mejorados del complejo de activación transcripcional notch y métodos para el uso de estos.
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
CY1125788T1 (el) Παραγωγα ναφθυριδινονης και χρηση αυτων στην αντιμετωπιση της αρρυθμιας
PY1421755A (es) Derivados de la pirazolopirrolidina y usi en el tratamiento de enfermedades
AR110330A1 (es) Uso de derivados de bencimidazol para escape ácido nocturno
PY1446505A (es) Compuestos derivados de piridilo biciclicos fusionados a anilo como inhibidores de fgfr4